Quick Answer
Oncotelic Therapeutics, Inc. reported Cash and Equivalents of $170.4 thousand for fiscal year 2023.
Oncotelic Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $170.4K | -29.4% |
| 2022 | $241.5K | -57.5% |
| 2021 | $568.8K | +20.0% |
| 2020 | $474.0K | +478.3% |
| 2019 | $82.0K | +3181.2% |
| 2018 | $2.5K | -99.8% |
| 2017 | $1.11M | -68.5% |
| 2016 | $3.54M | -87.0% |
| 2015 | $27.29M | -9.1% |
| 2014 | $30.03M | +507.2% |
| 2012 | $4.95M | -50.4% |
| 2011 | $9.97M | +116.7% |
| 2010 | $4.60M | -67.0% |
| 2009 | $13.93M | -23.8% |
| 2008 | $18.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $409.0K | +174.5% | +364.7% |
| June 30, 2025 | $88.0K | +21.9% | +11.2% |
| March 31, 2025 | $79.2K | -58.1% | -8.1% |
| December 31, 2024 | $86.1K | -49.5% | -42.2% |
| September 30, 2024 | $149.0K | — | +106.4% |
| June 30, 2024 | $72.2K | — | -61.8% |
| March 31, 2024 | $189.0K | — | +10.9% |
| December 31, 2023 | $170.4K | — | -32.9% |
- Oncotelic Therapeutics, Inc. showed a decrease of -29.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2023 period, Oncotelic Therapeutics, Inc.’s cash and equivalents has declined by 99.1% (from $18.27 million to $170.4 thousand).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: